Zura Bio's Tibulizumab Phase 2 progress signals multi-disease sales potential
Zura Bio is advancing tibulizumab with a dual-target mechanism aimed at T-cell and B-cell pathways. Phase 2 HS data due Q4 2026 and TibuSURE results in H1 2027 underpin near-term catalysts, with a third disease trial planned by end-2026. Analysts assign multi-billion sales potential and a robust cash runway into 2028, supporting a material re-rating if readouts are favorable.
View signal analysis